UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~December 514, 2010

Osteologix, Inc.
(Exact name of registrant as specified in its charter)


Delaware	333-112754	32-0104570
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)


4415 Cox Road Glen Allen, Virginia		23060
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (804) 747-6027

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 58.0201. ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Events

On ~~October~~December 514, 2010, ~~Bobby~~Osteologix, WInc. ~~Sandage~~(the ~~Jr.,~~“Company”) ~~Ph.D.~~announced ~~resigned~~that asthe Company intends to file a ~~director~~Form 15 ofwith ~~Osteologix,~~the ~~Inc.~~ Securities and Exchange Commission (the “~~Company~~SEC”) ~~effective~~to ~~immediately.~~voluntarily ~~Mr. Sandage~~deregister ~~previously~~its common stock and intends to ~~served~~suspend asits areporting ~~member~~obligations ofunder the ~~audit~~Securities ~~committee~~Exchange ~~and~~Act ~~the~~of ~~compensation~~1934, ~~committee~~as amended, beginning January 1, 2011. As a consequence of the deregistration, it is anticipated that the Company’s ~~board~~common ofstock ~~directors.~~will Mrno longer be eligible for trading on the Over-the-Counter Bulletin Board. ~~Sandage~~ ~~did~~The Company ~~not~~anticipates ~~resign~~that ~~because~~its ofcommon stock will be quoted on the Pink Sheets, a ~~any~~centralized ~~disagreement~~electronic ~~with~~quotation service for over-the-counter securities. However, the Company can give no assurance that trading in its stock will continue on the Pink Sheets or on any ~~matter~~other ~~relating~~securities toexchange or quotation medium. Following deregistration, the Company’s intends to communicate with its ~~operations,~~shareholders ~~policies~~through orits ~~practices~~website and periodic press releases.

OnIn ~~October 6~~addition, in ~~2010,~~conjunction ~~the~~with ~~Company~~plans ~~received~~to anminimize ~~action by written consent of stockholders holding a majority of~~ the Company’s ~~common~~corporate ~~stock~~overhead expenses ~~signed by Nordic Biotech K/S~~ and ~~Nordic~~ ~~Biotech~~focus ~~Opportunity~~its ~~Fund~~business ~~K/S~~activities, (the ~~“Written Consent”) (1) removing Jeremy Curnock Cook from his position as director of the~~ Company ~~without~~ ~~cause~~plans ~~and (2) appointing each of Enda Kenny and David O’Flynn~~ to ~~fill~~close ~~the~~its ~~vacancies created by the resignation of~~US ~~Mr. Sandage~~office ~~and~~in ~~the~~Glen ~~removal~~Allen, ~~of Mr. Cook~~Virginia, ~~each~~consolidate toits ~~hold~~US ~~such~~parent ~~office until~~company ~~the~~into ~~next annual meeting of the stockholders and until their successors~~its ~~have~~direct ~~been~~Irish ~~duly~~subsidiary, ~~elected~~Osteologix ~~and~~Holdings ~~qualified~~Ltd. (~~collectively,~~subject ~~the~~to ~~“Director~~stockholder ~~Changes”~~approval)., ~~The~~and, ~~Written~~following ~~Consent provides that~~ the ~~Director~~proposed ~~Changes~~consolidation, ~~will~~conduct ~~be effective~~all ~~on the date that is 20 calendar days immediately following the~~future ~~mailing~~activities offrom aits ~~Schedule 14C~~office ~~Information Statement to the stockholders of the Company but~~ in ~~no event later than November 10~~Dublin, ~~2010~~Ireland.

~~The~~A ~~Company~~copy ~~intends~~of ~~to file with~~ the ~~U.S. Securities and Exchange Commission (the “SEC”) a~~press ~~Schedule 14C~~release ~~Information Statement~~ regarding ~~the~~this ~~Director~~announcement ~~Changes.~~is ~~After the~~attached ~~SEC~~hereto ~~review~~as ~~period has been satisfied, the Company will distribute to the Company’s stockholders such Schedule~~Exhibit ~~14C Information Statement to notify them of the Director Changes in accordance with the rules and regulations of the SEC~~99.1 ~~Pursuant to the rules~~ and ~~regulations of the SEC, the~~ ~~Schedule 14C~~is ~~Information~~incorporated ~~Statement~~herein ~~must~~by ~~be sent to stockholders at least 20 calendar days prior to the earliest date on which the proposed corporate action may be taken~~reference.

~~Upon~~Item ~~effectiveness of the Director Changes, Mr~~9. ~~Kenny and Mr~~01. ~~O’Flynn~~ ~~will~~Financial ~~receive the~~Statements standard compensation for members of the board of directors as set forth in the Company’s definitive proxy statement on Schedule 14A filed with the SEC. The Company has not yet determined on which committee(s) of the board of directors Mr. Kenny and Mr. O’Flynn will serve upon effectiveness of the Director Changes. Mr. O’Flynn currently serves as the managing director of Osteologix Ltd., a wholly-owned subsidiary of the Company organized in Ireland. Exhibits

2(d) Exhibits 99.1 Press Release of Osteologix, Inc. dated December 14, 2010

~~Pursuant to the requirements of the~~SIGNATURES ~~Securities Exchange Act of 1934, the Registrant has duly caused this report to~~ ~~be signed on its behalf by the undersigned thereunto duly authorized.~~

~~OSTEOLOGIX~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to ~~INC~~be signed on its behalf by the undersigned thereunto duly authorized.

~~By: /s/ Philip J~~OSTEOLOGIX, INC. ~~Young Philip J. Young President and Chief Executive Officer~~

~~Date~~By: ~~October 8,~~/s/ ~~2010~~Philip J. Young Philip J. Young President and Chief Executive Officer

3Date: December 15, 2010

EXHIBIT INDEX


Exhibit No.		Description

EX-99.1		Press Release of Osteologix, Inc. dated December 14, 2010

Filing Compare · Osteologix, Inc.